Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mepivacaine is an amide-type local anesthetic used for local or regional analgesia or anesthesia. It is chemically related to bupivacaine and pharmacologically similar to lidocaine. Mepivacaine works by stabilizing the neuronal membrane and blocking sodium channels on the intracellular surface of nerve cells. This action prevents the initiation and transmission of nerve impulses required for pain sensation[2][5][8]. It is indicated for infiltration anesthesia (injection into tissue), nerve block (injection near nerves), epidural anesthesia (injection into the epidural space), and dental procedures in both adults and pediatric patients[1][4][5]. Mepivacaine is rapidly metabolized in the liver with a half-life of 1.9–3.2 hours in adults[2][5]. Systemic absorption can affect both cardiovascular and central nervous systems at high concentrations[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mepivacaine.